What is Epic Sciences?
Founded in 2008 and headquartered in San Diego, Epic Sciences Inc. specializes in the development of advanced diagnostic tests designed to molecularly characterize circulating tumor cells (CTCs) in the blood. By providing actionable insights into tumor biology, the company enables clinicians to make more informed treatment decisions, effectively bridging the gap between complex genomic data and patient care. Its platform is instrumental in the shift toward personalized medicine, offering a non-invasive alternative to traditional tissue biopsies and enhancing the monitoring of cancer progression throughout the patient journey.
How much funding has Epic Sciences raised?
Epic Sciences has raised a total of $220.5M across 9 funding rounds:
Series C
$30M
Debt
$15M
Series D
$40M
Other Financing Round
$52M
Debt
$1M
Series F
$43M
Series G
$24M
Series C (2014): $30M supported by Domain Associates, Pfizer Venture Investments, Roche, and Arcus Ventures
Debt (2015): $15M featuring Silicon Valley Bank
Series D (2017): $40M backed by Genomic Health, Domain Associates, Hermed Capital, and Altos Capital Partners
Other Financing Round (2018): $52M with participation from Blue Ox Healthcare Partners
Debt (2020): $1M led by PPP
Series F (2022): $43M supported by Blue Ox Healthcare Partners and Arsenal Capital Partners
Series G (2023): $24M featuring Arsenal Capital Partners, HC Domain Ventures, Deerfield, Blue Ox Healthcare Partners, and Labcorp
Key Investors in Epic Sciences
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a focus on biopharmaceutical, device, and diagnostic companies.
Blue Ox Healthcare Partners
Blue Ox Healthcare Partners is a commercial-stage growth investor focused on precision health and individualized medicine, guiding companies through the commercialization process.
Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies, utilizing a build-for-tomorrow philosophy.
What's next for Epic Sciences?
With the support of its latest financing, Epic Sciences is well-positioned to scale its commercial operations and expand the clinical utility of its diagnostic platform. The company's strategic focus remains on deepening its integration within the oncology ecosystem, leveraging partnerships with major diagnostic and pharmaceutical entities to accelerate the adoption of its technology. As the firm moves beyond its development phase, the focus will likely shift toward broader market penetration and the validation of its tests in diverse therapeutic settings, ensuring that its molecular intelligence becomes a standard component of precision cancer care.
See full Epic Sciences company page
